ECSP109947A - Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue - Google Patents

Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue

Info

Publication number
ECSP109947A
ECSP109947A EC2010009947A ECSP109947A ECSP109947A EC SP109947 A ECSP109947 A EC SP109947A EC 2010009947 A EC2010009947 A EC 2010009947A EC SP109947 A ECSP109947 A EC SP109947A EC SP109947 A ECSP109947 A EC SP109947A
Authority
EC
Ecuador
Prior art keywords
peptide
dengue virus
virus input
inhibitory
optimized
Prior art date
Application number
EC2010009947A
Other languages
English (en)
Inventor
Scott Michael
Sharon Isern
Ram Samudrala
Robert Garry
Joshua Costin
Ekachai Jenwitheesuk
Original Assignee
Florida Gulf Coast University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Gulf Coast University filed Critical Florida Gulf Coast University
Publication of ECSP109947A publication Critical patent/ECSP109947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con inhibidores de la entrada de péptido y métodos para determinar tales inhibidores que se pueden ligar a regiones de virus que tienen proteínas E clase 2, tal como la proteína E del virus del dengue, como candidatos para compuestos antivirales in vivo.
EC2010009947A 2007-07-13 2010-02-09 Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue ECSP109947A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94971007P 2007-07-13 2007-07-13

Publications (1)

Publication Number Publication Date
ECSP109947A true ECSP109947A (es) 2010-05-31

Family

ID=40549787

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009947A ECSP109947A (es) 2007-07-13 2010-02-09 Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue

Country Status (10)

Country Link
US (1) US8541377B2 (es)
EP (1) EP2178903B1 (es)
CN (1) CN101801996B (es)
AP (1) AP3172A (es)
AT (1) ATE547425T1 (es)
AU (1) AU2008311220B2 (es)
CO (1) CO6260142A2 (es)
DK (1) DK2178903T3 (es)
EC (1) ECSP109947A (es)
WO (1) WO2009048658A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
US10639380B2 (en) * 2016-12-06 2020-05-05 Ennaid Therapeutics, LLC Flavivirus-binding, entry-obstructing, protease-resistant peptide (RI57)
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same

Also Published As

Publication number Publication date
EP2178903A4 (en) 2010-11-17
CN101801996B (zh) 2013-06-12
WO2009048658A9 (en) 2009-06-11
HK1145693A1 (en) 2011-04-29
EP2178903B1 (en) 2012-02-29
AU2008311220A1 (en) 2009-04-16
US8541377B2 (en) 2013-09-24
CO6260142A2 (es) 2011-03-22
WO2009048658A2 (en) 2009-04-16
US20110112031A1 (en) 2011-05-12
ATE547425T1 (de) 2012-03-15
AP3172A (en) 2015-03-31
DK2178903T3 (da) 2012-06-18
EP2178903A2 (en) 2010-04-28
CN101801996A (zh) 2010-08-11
AU2008311220B2 (en) 2013-10-03
WO2009048658A3 (en) 2009-07-23
AP2010005141A0 (en) 2010-02-28

Similar Documents

Publication Publication Date Title
ECSP109947A (es) Péptido (dn81) optimizado inhibitorio de la entrada del virus del dengue
CY1125705T1 (el) Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
MX2009012343A (es) Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
MX380778B (es) Compuestos y métodos para la modulación de expresion de proteína cinasa de distrofia miotónica (dmpk).
CY1123304T1 (el) Αναστολη πεπτιδιων που προερχονται απο μεταγραφημα 1 τυπου trem (tlt-1) και χρησεις αυτωn
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
EA201591559A1 (ru) Терапевтические пептиды
DK2459715T3 (da) Fremgangsmåde til at oprense rekombinant adamts13 og andre proteiner og sammensætninger deraf
ECSP17039547A (es) Nuevas normalizaciones y dispositivos médicos para la preparación de plasma rico en plaquetas (prp) o concentrado de médula ósea (bmc) solos o combinados con ácido hialurónico
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
MX383346B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
EA201792245A1 (ru) Биоконъюгаты и их применения
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
BRPI0922913A2 (pt) Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
MX2015001553A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
MX2016002166A (es) Anticuerpos.
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.